text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999



 RTKs (Receptor tyrosine kinases) are transmembrane glycoproteins present on cell surface that activate various kinds of main cell signaling pathways like MAPK pathway and PI3K pathway. They're important molecules in biological phenomenon to control basic cell activities such as proliferation, differentiation, survival and death. Their excess expression and active mutation have been reported in cancer cells. Numerous specific low molecular-weight drugs and antibodies designed to inhibit their activities have been developed.

 EGFR is a transmembrane protein receptor for members of EGF family (Epidermal Growth Factor family) of extracellular protein ligands EGFR is a member of ErbB family of receptors which includes EGFR (ErbB1), HER2 (ErbB2), HER3, HER4. Anti-tumor agents, including Dacomitinib (Product code : D5450), have been developed as a result of extensive studies of ligand binding to various ErbB receptors.


 FGF (Fibroblast Growth Factor) is a protein that is involved in wide variety of processes related to normal development of various cells including fibroblasts, as well as angiogenesis, wound healing and so on. The mammalian FGFR (FGF receptor) family has four members: FGFR1, FGFR2, FGFR3 and FGFR4.


 PDGF (Platelet-Derived Growth Factor) is mainly involved in the regulation of migration and proliferation of mesenchymal cells. PDGRF (PDGF Receptor) family belongs to type III class of RTK receptors, and includes PDGFR, CSF-1R, KIT, FLT3 among others. The over-expression of PDGF and PDGFR is believed to correlate with development of arteriosclerosis and fibrous growth disease.


 VEGF (Vascular Endothelial Growth Factor) is signaling protein which plays an essential role in angiogenesis, enhancement of proliferation of endothelial cell and vasculogenesis. It deeply associated with cancer metastasis and inflammatory disease, therefore, VEGF and VEGFR (VEGF Receptor) are very important target molecules for Pharmaceutical R&D.


 RET (Rearranged During Transfection) protein is activated as a receptor tyrosine kinase by interacting with GDNF (Glial Cell Line Derived Neuotrophic Factor), such interaction activates signaling pathways including PI3K-Akt signaling pathway and MAPK signaling pathway. It has been reported that a certain type of mutation in RET, known as ‘rearrangement’, fuse the RET gene with other nearby genes, resulting in a RET protein that contains parts of other proteins which makes it hyperactive oncogene and correlates with development of thyroid gland cancer and lung cancer.




13 项结果 显示
  • 1(current)
  • 2
查看:  名单
产品编码 T3575
CAS RN 136831-48-6
纯度/分析方法 >98.0%(GC)

产品编码 T3667
CAS RN 10537-47-0
纯度/分析方法 >98.0%(GC)

产品编码 T3576
CAS RN 136831-49-7
纯度/分析方法 >98.0%(HPLC)

产品编码 T3503
CAS RN 118409-57-7
纯度/分析方法 >98.0%(GC)

产品编码 W0013
CAS RN 211555-04-3
纯度/分析方法 >98.0%(HPLC)

产品编码 U0103
CAS RN 168835-82-3
纯度/分析方法 >98.0%(HPLC)

产品编码 A2704
CAS RN 133550-35-3
纯度/分析方法 >98.0%(HPLC)(N)

产品编码 T3504
CAS RN 133550-49-9
纯度/分析方法 >97.0%(HPLC)

产品编码 T3540
CAS RN 133550-37-5
纯度/分析方法 >98.0%(HPLC)

产品编码 T2962
CAS RN 133550-30-8
纯度/分析方法 >98.0%(T)(HPLC)

产品编码 T3074
CAS RN 2826-26-8
纯度/分析方法 >98.0%(GC)

产品编码 T2944
CAS RN 153436-53-4
纯度/分析方法 >98.0%(HPLC)

产品编码:   T3575 | 纯度/分析方法   >98.0%(GC)

产品编码:   T3667 | 纯度/分析方法   >98.0%(GC)

产品编码:   T3576 | 纯度/分析方法   >98.0%(HPLC)

产品编码:   T3503 | 纯度/分析方法   >98.0%(GC)

产品编码:   W0013 | 纯度/分析方法   >98.0%(HPLC)

产品编码:   U0103 | 纯度/分析方法   >98.0%(HPLC)

产品编码:   A2704 | 纯度/分析方法   >98.0%(HPLC)(N)

产品编码:   T3504 | 纯度/分析方法   >97.0%(HPLC)

产品编码:   T3540 | 纯度/分析方法   >98.0%(HPLC)

产品编码:   T2962 | 纯度/分析方法   >98.0%(T)(HPLC)

产品编码:   T3074 | 纯度/分析方法   >98.0%(GC)

产品编码:   T2944 | 纯度/分析方法   >98.0%(HPLC)

  • 1(current)
  • 2